Washington, D.C, November 12th-15th
This year marks the inaugural joint appearance of SB Drug Discovery, Sygnature Discovery, and NuChem Sciences at SfN’s annual Neuroscience conference following the acquisition. Anticipate an excellent week ahead, featuring a stellar line up of presenters from each site, all enthusiastic about engaging with you to showcase our unified capabilities in the field of neuroscience.
View Our Poster Presentations
SB Drug Discovery readily awaits presenting two posters that highlight our most recent advancement in ion channel and receptor research. Our dedicated presenters will be available during the specified times to address any inquiries you may have.
Monday November 13th, 1pm-5pm
A cascade of cell-based assays designed to characterize 5HT2A receptor ligands and aid the investigation of signaling pathway bias.
Author: Lesley Gerrard,
Presenter: David Dalrymple
Tuesday November 14th, 8am-12pm
High-throughput electrophysiology tools to measure TMEM175 proton conductance.
Author: Davide Pau,
Presenter: Davide Pau
Engage with Us at Our Exhibition Booth
Experience first-hand the breadth of our ion channel and receptor drug discovery capabilities by visiting us at booth 930. Additionally, explore Sygnature Discovery’s offerings at booth 932, conveniently located side by side.
About the Meeting
Neuroscience 2023 is an excellent opportunity for scientists from around the world to congregate and present research, attend events and network with some of the top scientists in the field.
About SB Drug Discovery
SB Drug Discovery is an industry leader in specialist contract research, delivering high quality cell lines and conducting screening assays against a broad range of targets. Our services, built on experience amassed across more than 20 years of global project work, help you quickly generate trustworthy data and accelerate the discovery of novel therapeutics.
About Sygnature Discovery
Sygnature Discovery is a world-leading integrated drug discovery Contract Research Organization. With over 1,000 employees, which includes 900 scientists, partners with global pharma, biotech, and not-for-profit organization. Sygnature Discovery has delivered over 40 novel pre-clinical and 22 clinical compounds with our scientists names on over 170 patents. Therapeutic areas of expertise include neuroscience, oncology, inflammation and immunology, metabolic diseases, infectious diseases, fibrotic diseases, and more.
https://www.sygnaturediscovery.com/
About NuChem Sciences
NuChem Sciences, which employs 300 scientific and support staff, is headquartered in Montreal, Quebec and offers a range of standalone and integrated discovery services in chemistry, biochemistry, in-vitro biology, DMPK, structural biology and in vivo pharmacology.
For more information and to view the full meeting agenda, view here.
We look forward to seeing you there!
